32 Biosciences
Pioneering gut mucosal-immune science
32 Biosciences develops therapeutics and diagnostic solutions to prevent and treat gastrointestinal (GI) diseases by targeting the gut mucosal-immune system. The company combines a GI Discovery Platform that measures metabolomic signatures of the gut mucosal-immune system with a therapeutic program centered on mucosal immune modulators (MIM).
Solutions and lead programs
Key offerings and focus areas:
- GI Discovery Platform — measures metabolomic signatures to enable therapeutic discovery, development, and clinical decision support.
- CS Therapeutic Platform — MIM therapeutics designed to restore and protect the mucosal-immune barrier in the GI tract; lead asset: CS-0003.
- Primary goal: prevent and treat GI disease through novel therapeutics and data-driven discovery tools.
Location and contact
Headquartered in North Chicago, IL. Contact: [email protected].